ID | 1113 |
Name of the vaccine | BAT |
Microbe | Bacteria |
Disease name | Botulism |
Name of bacteria | Clostridium botulinum |
Type of vaccine | Toxoid |
Nucleic acid content | DNA |
Age | NA |
Description of the vaccine | Botulism antitoxin heptavalent (A, B, C, D, E, F, G) - (Equine). |
Name of the manufacturer | Cangene Corporation, a subsidiary of Emergent BioSolutions Inc. |
Name of the manufacturing country | Canada |
Year of manufacture | 2013 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive anaerobic bacterium. |
Efficacy | In guinea pig, 100% for neurotoxin serotype A, B, E and F, 97% in C and D.
In non-human primate, 47% survival rate. |
Vaccine formulation | Sterile suspension |
Dosage | Adults: One vial
Pediatric (1 to 17 years): 20-100% of adult dose
Infants: 10% of adult dose regardless of body weight |
Mechanism of action | Passive immunization with equine polyclonal antibody fragments. |
Route of administration | Intravenous |
Indications | Treatment of symptomatic botulism exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G. |
Export | NA |
Approval | US FDA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Headache, nausea, pruritus, urticaria, pyrexia, rash, chills and edema. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/85514/download |
Other name | NA |
Additional Links | NA
|